Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05579548

A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding

Sponsor: BioMarin Pharmaceutical

View on ClinicalTrials.gov

Summary

This is a Phase 4 observational study designed to assess the impact of Palynziq ® (pegvaliase) treatment in pregnant women with PKU and on their offspring who were exposed to pegvaliase at any time during pregnancy and breastfeeding.

Key Details

Gender

FEMALE

Age Range

Any - Any

Study Type

OBSERVATIONAL

Enrollment

50

Start Date

2022-11-22

Completion Date

2032-10-04

Last Updated

2026-03-24

Healthy Volunteers

Not specified

Interventions

DRUG

Pegvaliase

Pregnant women exposed to pegvaliase within 2 weeks prior to LMP.

Locations (4)

Syneos Health

Wilmington, North Carolina, United States

Metabolics and Genetics in Calgary (MAGIC)

Calgary, Canada

Universitaetsklinikum Hamburg Eppendorf

Hamburg, Germany

Ospedale San Paolo

Milan, Italy